| Document |
Document Title |
|
WO/2017/084627A1 |
The present invention relates to a lactam compound derivative, a medicine composition comprising the lactam compound derivative, and uses of the composition and the lactam compound derivative in preparation of a medicine for preventing o...
|
|
WO/2017/083702A1 |
In one aspect, the present disclosure provides diaryl compounds of the formula presented herein. The application also provides compositions and methods of treatment thereof. In some embodiments, these compounds are used in the treatment ...
|
|
WO/2017/083431A2 |
The present teachings relate to hydroxypyridinone and hydroxypyrimidinone derivatives, pharmaceutical compositions thereof, and methods of using such compounds to treat bacterial infections.
|
|
WO/2017/076355A1 |
The present invention provides a pyrimidine derivative and a use thereof. The pyrimidine derivative is the compound shown in formula I or a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof, wherein, R1, R...
|
|
WO/2017/077911A1 |
A compound represented by formula (I) or an N-oxide compound thereof has an excellent controlling effect on arthropod pests. (In the formula, A1 represents a nitrogen atom or CR4; R4 represents a hydrogen atom or the like; R1 represents ...
|
|
WO/2017/076264A1 |
The present invention relates to a class of compounds as shown in general formula I or pharmaceutically acceptable salts thereof, a preparation method therefor, application thereof as a small molecule tool that functions as a GPR84 agoni...
|
|
WO/2017/078123A1 |
In a method for producing a dedimethoxybenzylation compound that removes a dimethoxybenzyl group, in the presence of an acid, from a compound, in which the dimethoxybenzyl group is bonded to a nitrogen atom, a dedimethoxybenzylation comp...
|
|
WO/2017/073709A1 |
A compound represented by formula (1) or salt thereof which has an inhibitory effect on mPGES-1, and is useful as an active ingredient for a medicinal drug for preventing and/or treating a disease such as inflammation, pain, rheumatism, ...
|
|
WO/2017/071419A1 |
Disclosed is a method for preparing Rociletinib. By means of a condensation reaction of easily obtainable raw materials 5-trifluoromethyluracil and 4-(4-acetylpiperazin-1-yl)-2-methoxyaniline to obtain 2-[[4-(4-acetyl-1-piperazinyl)-2-me...
|
|
WO/2017/071410A1 |
A crystalline form of iodosulfuron-methyl-sodium of formula (I), the crystal preparation process, the analyses of the crystal through various analytical methods, using the crystal to prepare stable agrochemical formulation and the use of...
|
|
WO/2017/075394A1 |
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A...
|
|
WO/2017/068070A1 |
The invention provides a series of substituted aryl pyrimidine compounds and the use of these compounds as therapeutics to treat or prevent neurodegenerative disorders, including Parkinson's disease. Compounds of the invention are also a...
|
|
WO/2017/068584A1 |
Ordered structures composed of a plurality of self-assembled peptide nucleic acid (PNA) monomers, and processes of generating same are provided. The plurality of PNA monomers includes modified PNA monomers which are N-protected PNA monom...
|
|
WO/2017/069173A1 |
Provided is a compound that has cholinergic muscarinic M1 receptor positive allosteric modulator activity and is useful as a medicine, e.g., a preventative or treatment agent for Alzheimer's disease, schizophrenia, pain, sleep disorders,...
|
|
WO/2017/066428A1 |
Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I throu...
|
|
WO/2017/066650A1 |
The use of mass defect signatures to impart milliDalton mass differences between isotopically labeled peptides at the MS1-level allows multiplex quantification without the increased mass spectral complexity that occurs with mass differen...
|
|
WO/2017/063103A1 |
The present invention relates to 2,5-diaminopyrimidine-based Bruton's tyrosine kinase inhibitors. The present invention also relates to 2,5-diaminopyrimidine-based affinity probes for Bruton's tyrosine kinase and uses of such probes for ...
|
|
WO/2017/061532A1 |
The present invention provides a compound represented by formula (1) (in the formula, X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description) and a pharmaceutically acceptable salt thereof, which are useful as a va...
|
|
WO/2017/060917A1 |
The present invention relates to an improved process for preparation of methyl (E)-2-{2- [6-(2-cyanophenoxy) pyrimidin-4-yloxy] phenyl}-3-methoxyacrylate of formula (I) in free form or in agro chemically acceptable salt form useful as a ...
|
|
WO/2017/058645A1 |
Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a...
|
|
WO/2017/058689A1 |
The invention is directed to novel anhydrous crystalline butenedioate salt form 1 of Compound I, which is a modulator of muscarinic M1 receptors. The novel crystalline forms of compound I are useful in the treatment or prevention of Alzh...
|
|
WO/2017/059080A1 |
The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAKl (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's dis...
|
|
WO/2017/057119A1 |
The pyrimidine compound represented in formula (1) is effective as a pest control agent.
|
|
WO/2017/059280A1 |
This invention is in the area of improved therapeutic combinations for and methods of treating selected cancers using selected pyrimidine compounds having pan-TAM or Mer/Axl dual receptor tyrosine kinase inhibitory activity in combinatio...
|
|
WO/2017/059085A1 |
The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAKl (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's dis...
|
|
WO/2017/057120A1 |
The pyrimidine compound represented in formula (1) is effective as a pest control agent.
|
|
WO/2017/058691A1 |
This invention provides novel processes for the preparation of compounds such as 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)met
hyl]benzo[h]-quinazolin-4(3H)-one, salts and derivatives thereof. The compounds synthesized by ...
|
|
WO/2017/057121A1 |
The pyrimidine compound represented in formula (1) is effective as a pest control agent.
|
|
WO/2017/052308A2 |
One embodiment of the present invention provides a compound for an organic device, the compound comprising a functional group comprising a pyrimidine ring, and/or a functional group comprising a pyrimidine ring, which is included at a te...
|
|
WO/2017/053391A1 |
The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic port...
|
|
WO/2017/051251A1 |
Described inter alia are compounds according to formula (I): or a pharmaceutically acceptable salt thereof, and uses in methods for the modulation of flap endonuclease 1 (FENl), Xeroderma Pigmentosum Complementation Group G protein (XPG)...
|
|
WO/2017/050111A1 |
The invention relates to a crystal form H and a preparation method of a 5-[2,6-Di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-
2-pyridinamine monohydrochloride. An x-ray powder diffraction pattern of the crystal form H in 25°C com...
|
|
WO/2017/049992A1 |
The present invention provides an EGFR kinase inhibitor and a preparation method and use thereof. Specifically, the present invention provides a compound as shown in formula (I), the definition of each group therein being as described in...
|
|
WO/2017/049409A1 |
Disclosed are compounds of general formula (I) that promote readthrough of a premature termination codon (PTC) of an RNA molecule in a translation system, and their use, alone or in combination with other compounds, such as aminoglycosid...
|
|
WO/2017/051354A1 |
Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of HIV; including the prevention of the p...
|
|
WO/2017/047602A1 |
Provided is a compound presenting high efficacy in diseases caused by Trichophyton by having excellent antifungal activity against Trichophyton, which is a major causative organism of superficial mycoses. A biaryl derivative represented ...
|
|
WO/2017/049321A1 |
Described herein are compounds and compositions, and methods of making and their use as effective agents against mycobacterial infections.
|
|
WO/2017/047594A1 |
Provided is a nucleoside derivative represented by formula (1). (In formula (1), Y represents an unfused aromatic or heterocyclic hydrocarbon group or a fused polycyclic based hydrocarbon group, W1 represents a hydrogen atom, a hydroxyl ...
|
|
WO/2017/049096A1 |
The present invention relates to a process for preparing a compound of 5 or 5*, or a mixture thereof, and/or a compound of 14 or 14*, or a mixture thereof, that is useful as an antifungal agent. In particular, the invention seeks to prov...
|
|
WO/2017/049080A1 |
The present invention relates to a process for preparing a compound of 5 or 5*, or a mixture thereof, that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compounds 7, 7* and ...
|
|
WO/2017/045931A1 |
The present invention relates to compounds according to formula (I) and to heat-curable resin compositions based on polymaleimide resin systems comprising such compounds as co-monomers:, (I) wherein Dis an x-functional group; and x is an...
|
|
WO/2017/042828A2 |
The present invention provides processes for the preparation of Selexipag compound of formula (1). The present invention also provides processes for the preparation of 4-[(5,6-diphenyl-pyrazin-2-yl)-isopropyl -amino]-butan-1-ol (2), and ...
|
|
WO/2017/043886A1 |
The present specification provides a heterocyclic compound and an organic light emitting element using the same.
|
|
WO/2017/044302A1 |
Certain aspects of the present invention generally relate to compositions and methods for treating a bone disease, for example a genetic bone disease. In one embodiment the bone disease is fibular hemimelia, proximal femoral focal defici...
|
|
WO/2017/041771A1 |
The object of the invention is a preparation method of Ceritinib of formula (I) and its salts wherein 2-isopropylthioaniline is used in the first step. Even under mild conditions, it provides an intermediate, which is further oxidized to...
|
|
WO/2017/041701A1 |
Provided are compounds that can be used for treating cardiovascular diseases and compositions containing the compounds. The compounds and the compositions can improve lipid metabolism disorders by increasing high-density lipoprotein chol...
|
|
WO/2017/040896A1 |
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...
|
|
WO/2017/040895A1 |
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...
|
|
WO/2017/040971A1 |
This disclosure features methods for treating lysosomal storage disorders (e.g. MPS) and/or neurodegenerative diseases (e.g., Alzheimers disease), which include administering to a subject (e.g., a human patient) in need of such treatment...
|
|
WO/2017/040898A1 |
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...
|
